flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 just got FDA-approved for disease. This changes everything. January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in type 2 diabetes with CKD. This Semaglutide in CKD - The

Medication for hair restoration can be highly effective, especially when treatment starts early, the underlying cause has been accurately diagnosed, and the medication is taken consistently under medical supervision

Many people in this range have undiagnosed prediabetes, subclinical hypertension, or dyslipidemia that would qualify them if it were simply identified and documented

Vitamin B1 and B6 appointments are simple to schedule and designed to fit comfortably into busy routines

They could be slightly overweight

Prescription GLP-1 drugs tend to deliver slightly more aggressive results-15 to 30 pounds over 3 to 6 months-but with a higher risk profile